Evenity (Romosozumab) Cost in Montana 2026

What Does Evenity (Romosozumab) Actually Cost in Montana?

The Amgen/UCB wholesale acquisition cost (WAC) for romosozumab is $1,825 per monthly dose, making the full 12-month treatment course approximately $21,900 at sticker price. Cash-pay prices at Montana retail pharmacies track closely to WAC because there is no meaningful generic competition. Patients without insurance or assistance programs pay close to this figure out of pocket.

Romosozumab is a sclerostin inhibitor approved by the FDA in April 2019 for postmenopausal women at high or imminent risk of fracture. The FDA label specifies a dose of 210 mg given as two consecutive 105 mg subcutaneous injections once monthly for 12 doses, after which patients typically transition to antiresorptive therapy such as alendronate or denosumab. [1]

Why the Price Is So Steady in Montana

Montana has no state-level drug price negotiation statute comparable to those enacted in some coastal states. The Montana Insurance Commissioner's office regulates insurer conduct but does not set pharmaceutical WAC. That means the pharmacy shelf price for Evenity tracks the national WAC almost exactly, unlike states with supplemental rebate agreements.

How Romosozumab Compares to Other Osteoporosis Biologics

For context, teriparatide (Forteo) carries a list price near $3,000 per month. Denosumab (Prolia) lists at roughly $900 per dose given every six months, or about $1,800 per year. Romosozumab at $21,900 per course is substantial but finite. Bisphosphonates such as generic alendronate cost under $20 per month. The choice between agents depends on fracture-risk severity, DEXA T-score, and tolerability, not on price alone. [2]

Montana Medicaid Coverage for Evenity (Romosozumab)

Montana Medicaid does not cover romosozumab as of 2026. The Montana Department of Public Health and Human Services (DPHHS) Preferred Drug List does not include Evenity in any covered tier. Patients enrolled in Healthy Montana Kids Plus or the regular Medicaid FFS program will receive a denial for romosozumab claims. [3]

What Medicaid Does Cover for Osteoporosis

Montana Medicaid does cover several osteoporosis therapies that may be clinically appropriate for some patients:

• Generic alendronate (oral bisphosphonate, weekly dosing)
• Generic risedronate
• Denosumab (Prolia) in select cases with prior authorization
• Calcitonin nasal spray (limited indications)

Patients who cannot access romosozumab through Medicaid should discuss whether their fracture-risk profile warrants denosumab with prior authorization or sequential bisphosphonate therapy. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines recommend anabolic therapy first for patients at very high fracture risk (T-score below -3.0 or prior hip/vertebral fracture), which may provide grounds for a Medicaid exception request. [4]

Filing a Medicaid Exception Request

A prescribing provider can submit a prior authorization exception to Montana DPHHS Medicaid citing the AACE guideline language and the patient's specific T-score, fracture history, and failure of prior bisphosphonate therapy. Approvals are not guaranteed, but documented high-risk status and documented bisphosphonate failure strengthen the request considerably. [5]

Medicare Coverage for Romosozumab in Montana

Medicare Part B covers romosozumab under the buy-and-bill model because it is a physician-administered injectable. [6] The drug is infused (injected) in-office, the provider bills Part B directly, and the patient owes 20% coinsurance after the Part B deductible ($257 in 2026). For a $1,825 list-price injection, 20% coinsurance equals about $365 per dose before any supplemental coverage.

Medicare Part D and Supplement Plans

Part D (outpatient pharmacy benefit) does not typically cover drugs administered in a clinical setting; romosozumab falls under Part B for most patients. A Medigap (Medicare Supplement) plan that covers Part B coinsurance can bring the patient's monthly cost to near zero for the injection itself. Montana residents should compare Medigap Plan G or Plan N, which cover Part B coinsurance. The Medicare Rights Center offers free counseling at 800-333-4114. [7]

Medicare Advantage Plans in Montana

Medicare Advantage plans covering Montana (including those offered by BlueCross BlueShield of Montana and Mountain Health CO-OP) may have different cost-sharing structures. Some Advantage plans negotiate lower effective rates through their Part B drug formularies. Patients should request a coverage determination letter before their first dose to avoid surprise bills. [8]

Commercial Insurance and Prior Authorization in Montana

Most commercial plans covering Montana residents include romosozumab on a specialty tier with prior authorization (PA) requirements. Common PA criteria mirror the FDA label and AACE guidelines:

• Postmenopausal status confirmed
• DEXA T-score of -2.5 or below (or -1.0 to -2.5 with documented high fracture risk)
• Prior trial or documented intolerance of an oral bisphosphonate
• No history of myocardial infarction or stroke in the past 12 months (FDA black box warning) [1]

Major Insurers Operating in Montana

Plans active in the Montana individual, small-group, and large-group markets include BlueCross BlueShield of Montana, PacificSource, Mountain Health CO-OP, and various employer self-funded plans. Each uses its own specialty formulary, but all are subject to Montana Insurance Commissioner rules on PA turnaround times (72 hours for urgent, 30 days for standard). [9]

Appealing a Denial

If a commercial insurer denies romosozumab, the prescriber should submit a peer-to-peer review request and include the ARCH trial data. The ARCH trial (N=4,093, NEJM 2017) showed romosozumab followed by alendronate reduced new vertebral fractures by 48% vs. Alendronate alone at 24 months (6.2% vs. 11.9%, P<0.001). [10] That magnitude of clinical benefit is strong use in a peer-to-peer appeal.

The Amgen/UCB Savings Card: How It Works in Montana

Amgen and UCB co-market Evenity and offer a co-pay savings card program for commercially insured patients. Eligible patients may pay $0 per dose for up to 12 doses in a calendar year, subject to program terms. The card does not apply to patients covered by any federal or state government program (Medicare, Medicaid, TRICARE, or VA). [11]

Eligibility Requirements

• Commercially insured (employer plan, ACA marketplace plan, or individual market plan)
• Resident of the United States (Montana qualifies)
• Not enrolled in any government-funded insurance program
• Prescription written by a licensed provider (telehealth prescriptions are accepted)

How to Enroll

Patients or their provider's office can enroll online at the Amgen patient support site or by calling 1-800-272-9376. The savings card is typically activated before the first injection. Providers administering the drug in-office apply the card at the point of billing. Mail-order specialty pharmacies such as CVS Specialty, Walgreens Specialty, or Accredo can also process the card for patients who self-inject. [12]

Compounded Romosozumab in Montana: Legal Status and Caveats

Compounded romosozumab is legally available in Montana through licensed 503A compounding pharmacies with a valid, patient-specific prescription from a licensed provider. Section 503A of the federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients. [13]

What 503A Means for Montana Patients

A 503A pharmacy dispenses compounded preparations only for individually identified patients. Montana Board of Pharmacy rules require the compounding pharmacy to hold an active Montana license (or a non-resident pharmacy license if shipping from out of state) and to comply with USP <797> sterility standards for any sterile injectable compound. [14]

Cost Differential

Because compounded romosozumab is not commercially manufactured at scale, some 503A pharmacies offer it at substantially lower prices than the Amgen/UCB brand product, and some list it as $0 out-of-pocket through specific patient programs. However, compounded biologics are not interchangeable with FDA-approved Evenity under federal law. The FDA does not evaluate the potency, purity, or stability of compounded versions of biologic drugs. [13]

Clinical Caution on Compounded Biologics

Romosozumab is a monoclonal antibody. Compounding a biologic is far more technically demanding than compounding a small-molecule drug such as testosterone or progesterone. The American Society of Health-System Pharmacists (ASHP) and the Endocrine Society have both raised concerns about the reliability of compounded biologics. [15] Patients considering a compounded version should ask the dispensing pharmacy for a certificate of analysis (CoA) confirming potency and sterility testing.

HealthRX Compounded vs. Brand Decision Framework for Montana Patients

| Factor | FDA-Approved Evenity | 503A Compounded Romosozumab | |---|---|---| | Regulatory oversight | Full FDA review of potency, purity, stability | No FDA review; state pharmacy board oversight only | | Clinical trial data | ARCH, FRAME trials support efficacy | No independent trial data | | Insurance billing | Billable to Part B, commercial plans | Not covered by insurance | | Out-of-pocket cost | $0 with savings card (commercially insured) | Varies; potentially lower cash price | | Recommended use | First-line when coverage available | Consider only after insurance exhausted |

Telehealth Prescribing of Romosozumab in Montana

Montana permits telehealth prescribing of prescription-only drugs, including specialty injectables, provided the prescriber holds an active Montana medical license and has established a valid patient-provider relationship. [16] The Montana Telehealth Alliance confirms that audio-video visits satisfy the examination requirement for most prescription medications.

Practical Workflow for Telehealth Patients

A Montana patient can complete a telehealth visit with an endocrinologist or primary care provider, provide DEXA scan results from a local imaging center, and receive a romosozumab prescription electronically. The prescription routes to a specialty pharmacy. Injections are then given by a local nurse, primary care office, or in some cases self-administered after training, depending on the prescriber's clinical judgment. [17]

Montana-Specific Patient Assistance Programs

Beyond the manufacturer savings card, Montana patients have access to several assistance pathways:

Amgen Safety Net Foundation

The Amgen Safety Net Foundation provides free Evenity to uninsured or underinsured patients who meet income eligibility criteria (generally at or below 500% of the federal poverty level). Applications are submitted by the prescribing provider. Processing typically takes 10 to 15 business days. [18]

NeedyMeds and RxAssist

Both NeedyMeds (needymeds.org) and RxAssist maintain databases of manufacturer patient assistance programs. These are free lookup tools, not dispensing services. Montana patients can search by drug name and insurance status to identify current program terms. [19]

Montana SHIP (State Health Insurance Assistance Program)

Montana SHIP provides free, unbiased Medicare counseling, including help understanding Part B drug coverage for romosozumab. Counselors are available at (800) 551-3191. This is particularly useful for Medicare-enrolled patients navigating the buy-and-bill process for the first time. [20]

Clinical Evidence Supporting Romosozumab Use

Understanding why romosozumab carries a premium price requires context on its efficacy. Two key trials established its place in therapy.

FRAME Trial (NEJM 2016)

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly to placebo in postmenopausal women with osteoporosis. At 12 months, romosozumab reduced new vertebral fractures by 73% relative to placebo (0.5% vs. 1.8%, P<0.001). Nonvertebral fracture reduction reached significance only in certain subgroups. [21]

ARCH Trial (NEJM 2017)

The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone for 24 months. Patients on the romosozumab-to-alendronate sequence had a 48% lower rate of new vertebral fractures (6.2% vs. 11.9%, P<0.001) and a 27% lower rate of nonvertebral fractures vs. Alendronate alone at 24 months. [10] The trial also identified a small but statistically significant increase in serious cardiovascular events in the romosozumab arm (2.5% vs. 1.9%), which led to the FDA black box warning against use in patients with prior myocardial infarction or stroke within the past year. [1]

AACE Guideline Position

The AACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "For patients at very high fracture risk, anabolic therapy (teriparatide, abaloparatide, or romosozumab) is recommended as initial pharmacological therapy." [4] The guidelines define very high risk as a T-score below -3.0, a recent fracture, or multiple fractures on therapy.

Who Qualifies for Romosozumab in Montana?

FDA-approved indications limit romosozumab to postmenopausal women at high or imminent fracture risk. Off-label use in men with osteoporosis exists in clinical practice and is supported by smaller trial data, but insurance coverage for off-label use is less consistent. [22]

Key Contraindications

• Prior myocardial infarction or stroke within the past 12 months (black box warning) [1]
• Hypocalcemia (must correct before initiating therapy) [1]
• Hypersensitivity to romosozumab or any component of the formulation

Pre-Treatment Checklist

Before the first injection, prescribers should confirm:

• Adequate calcium intake (at least 1,000 mg daily from diet plus supplement) [23]
• Vitamin D sufficiency (serum 25-OH-D above 30 ng/mL) [23]
• Dental examination if significant dental procedures are anticipated (osteonecrosis of the jaw risk, though lower with romosozumab than with bisphosphonates) [24]
• Cardiovascular risk assessment with documentation of no MI or stroke in prior 12 months [1]

Sequential Therapy After Romosozumab

Romosozumab's bone-building effect is transient. Bone mineral density gains reverse rapidly if patients do not transition to antiresorptive therapy immediately after the 12-month course ends. The ARCH trial demonstrated that transitioning to alendronate 70 mg weekly preserves and extends the gains. [10] The National Osteoporosis Foundation (NOF) and AACE both recommend initiating an antiresorptive agent within one month of the final romosozumab dose. [4]

Frequently Asked Questions